Faisal Khurshid, an analyst from Leerink Partners, has initiated a new Buy rating on Shattuck Labs (STTK).
Faisal Khurshid has given his Buy rating due to a combination of factors surrounding Shattuck Labs’ strategic focus on inflammatory bowel disease (IBD) through their novel approach with SL-325. This program represents a first-in-class strategy targeting the DR3 antagonist, which is set to enter Phase 1 trials in the third quarter of 2025. The anticipated single-dose data by the end of 2025 and multi-dose data in early 2026 are expected to serve as crucial proof-of-concept milestones that could significantly influence investor sentiment and stock performance.
Khushid’s optimism is fueled by the potential of SL-325 to offer broader immune regulation and possibly greater efficacy compared to existing TL1A inhibitors. The program’s focus on the membrane-bound DR3 receptor, as opposed to the soluble TL1A, could also address immunogenicity concerns associated with the TL1A class. Encouraging preclinical data, including a clean safety profile and promising pharmacokinetics, further support the potential of SL-325 to capture a substantial share of the competitive yet expansive IBD market.
Khurshid covers the Healthcare sector, focusing on stocks such as Pliant Therapeutics, Kymera Therapeutics, and Geron. According to TipRanks, Khurshid has an average return of 37.3% and a 52.46% success rate on recommended stocks.